|Product Name||Human TRANCE/TNFSF11/RANKL ELISA Kit|
|Customs Name||Human TRANCE/TNFSF11/RANKL ELISA Kit|
|Product Spec||96 T|
|SDS||SDS - EK1208|
|Assay Type||Sandwich ELISA|
|Suitable Sample Type||serum, plasma, cell culture supernates|
|Format||96-well strip plate|
|Storage||4℃ (unopened)standard stored at -20℃, others stored at 4℃ (opened)|
|Sample Volume||50 μl|
|Standard Curve Range||7.81 - 500 pg/ml|
|Spike Recovery Range||80 % -102 %|
|Mean Spike Recovery||91%|
|CV of Intra plate||4.2% -4.8%|
|CV of Inter plate||3.7% - 10.1%|
|Components||96-well polystyrene microplate coated with a monoclonal antibody against TRANCE
Human TRANCE Standard, lyophilized
TRANCE Detect Antibody
Assay Buffer (10×)
Washing Buffer (20×)
|Describtion||This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human TRANCE. The Human TRANCE ELISA is for research use only. Not for diagnostic or therapeutic procedures.
TNF-related activation-induced cytokine (TRANCE), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), receptor activator of nuclear factor kappa-B ligand (RANKL), is a member of the TNF superfamily. Cells known to express TRANCE include osteoblasts, CD4+ and CD8+ T cells, megakaryocytes, bronchial and intestinal epithelium and so on.
TRANCE appears to play a central role in both immune response and bone morphogenesis. During bone development and remodeling, TRANCE expression by osteoblasts in conjunction with M-CSF induces osteoclast formation and activation, resulting in bone resorption. This allows for subsequent bone deposition and remodeling. TRANCE also plays a role in pathological osteoporosis. Its inappropriate expression by activated lymphocytes and osteoblasts results in excessive joint and bone resorption vs. deposition. Overproduction of TRANCE is implicated in a variety of degenerative bone diseases, such as rheumatoid arthritis and psoriatic arthritis.